GLP-1 drugs are showing potential in treating alcoholism and substance use disorders alongside their established use in diabetes and weight management. Alcohol-related diseases kill approximately 178,000 Americans annually, significantly exceeding overdose deaths from drugs like fentanyl. A study indicated marked reductions in alcohol intake and binge drinking among obese alcohol consumers using GLP-1 drugs. Additionally, a long-term study in Sweden revealed that these drugs reduced hospitalization risks related to alcohol use disorder in obese patients with Type 2 diabetes, indicating possible broad applications of GLP-1 medications.
A study of 153 adults with a body mass index of 30 or higher found significant reductions in self-reported alcohol intake as well as in the number of drinks per drinking episode.
A large, 17-year observational study in Sweden showed that among problem drinkers with both obesity and Type 2 diabetes, GLP-1 drugs substantially decreased the risk for hospitalizations related to alcohol use disorder.
Collection
[
|
...
]